Excellent
Fully Aligned
Patient Risk:
Low
Summary
The claims provided about blood glucose monitoring interference are directly supported by the cited FDA label sections distinguishing intravenous vs subcutaneous ORENCIA, specifying GDH-PQQ-based monitoring and recommending alternative testing methods for IV patients only.
Category Scores
Accurate Statements
ORENCIA blood glucose monitoring should be adjusted due to blood glucose monitor interference (falsely elevated readings) with certain monitors, specifically for intravenous but not subcutaneous administration.
Supported by Prescribing Information 7.2 Blood Glucose Testing and 11 Description: IV contains maltose and may cause falsely elevated glucose readings with GDH-PQQ-based systems on the day of infusion; SC does not contain maltose. Also supported by 17 Patient Counseling Information (Blood Glucose Testing): recommendation applies to IV and not SC.
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The statement is label-supported and aims to prevent incorrect glucose readings for IV patients using affected monitor types; no label-relevant safety risks are introduced by the claim.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement